【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Overview of the AMD and Other Retinal Diseases Market, 2014-2025
2.1 Market to Make Rapid Strides to 2025
2.2 Lucentis Still Holds Over 60% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2025
3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2025
3.1 Will the Current Products Dominate the Market Through 2025?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
3.2.7 Lucentis Revenue Forecast 2014-2025
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea’s Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea’s Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2025
3.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT’s Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Avastin Revenue Forecast, 2014-2025
3.5 Visudyne (Valeant/Novartis): Declining Sales Throughout the Forecast Period
3.5.1 Visudyne Revenue Forecast, 2014-2025
3.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
3.6.1 Jetrea Revenue Forecast, 2014-2025
4. Wet AMD Segment, 2014-2025
4.1 Eylea: The Segment’s Biggest Short-Term Driver
4.2 Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Ophthotech Partners with Novartis for Fovista
4.3.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.5 The Move toward Combination Therapies
4.4 Other Growth Factor Targets in the Pipeline
4.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
4.4.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain Monoclonal Antibody Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 Verisome System and IBI-30089 (Icon Bioscience)
4.7.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
4.8.4 First Ophthalmic Complement Factor Inhibitor, AL-78898A (Alcon), Misses Primary Endpoint
4.8.5 Factor C5: A More Promising Target Addressed by ARC1905 Aptamer (Ophthotech) and LFG316 (Novartis)
4.8.6 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.7 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.8 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.9 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
4.8.10 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.11 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
4.9.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5. Dry AMD Segment, 2014-2025
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 High Hopes for Complement Inhibition in Dry AMD
5.5.1 Lampalizumab (Roche): The Big News of ARVO 2013
5.5.1.1 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
5.5.2 AL-78898A (Alcon): Phase 2 Trial in Dry AMD Terminated
5.5.3 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
5.7 Neuroprotection: One of Modern Medicine’s Holy Grails
5.7.1 Tandospirone (Alcon): No News on Serotonin 1A Agonist
5.7.2 NT-501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding Monoclonal Antibody Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD
6. Diabetic Retinopathy Segment, 2014-2025
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
6.4 Lucentis: The Game Changer for DR?
6.5 New Anti-VEGF Additions
6.5.1 Is Eylea Better than Lucentis and Avastin for DME?
6.6 Steroids in Development for DR
6.6.1 Iluvien (Alimera/pSivida): New Option in European Markets
6.6.2 A New Hope? Optina (Ampio Pharmaceuticals)
6.6.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.6.4 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.6.5 Cortiject (Santen): Prodrug Candidate
6.6.6 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
6.7 Other Products in Development for DR
6.7.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.7.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.7.3 TriLipix (Abbott): No New Development for Promising Drug
6.7.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.7.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.7.6 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
7. Regional Market Breakdown, 2014-2025
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market
8. Qualitative Industry and Market Analysis, 2015-2025
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges
9. Research Interviews
9.1 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 1)
9.1.1 MC-1101: Identifying and Treating Chiou Syndrome
9.1.2 Preventing Dry AMD Progression
9.1.3 Treating the Root Cause of Dry AMD
9.1.4 Phase 3: Endpoints and Prospects for MC-1101
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 2)
9.2.1 MC-1101: Progress in Clinical Trials
9.2.2 MC-1101 More Effective in Early to Mid-Range AMD
9.2.3 Partnerships and Expected Launch of MC-1101
10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
【レポート販売概要】
■ タイトル：加齢黄斑変性（AMD）及びその他の網膜疾患治療薬の世界市場：滲出型（ウェット型）、萎縮型（ドライ型）、糖尿病性網膜症■ 英文：Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN503045
■ 調査対象地域：グローバル
- 世界のマイクロファイバーレザー市場2015Global Microfiber Leather Industry Report 2015 is a professional and in-depth study on the current state of the Microfiber Leather industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Microfiber Leather market analysis is provided for the international markets including development trends, competitive …
- クローン病：企業動向PharmaPoint: Crohn’s Disease - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Crohn’s Disease - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn’s Disease Market. The report identifies and analyses the key companies shaping and driving the global Croh …
- 粘液性脂肪肉腫(Myxoid Liposarcoma)：世界の治験レビュー（2015年上半期版）Myxoid Liposarcoma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Myxoid Liposarcoma Global Clinical Trials Review, H1, 2015" provides data on the Myxoid Liposarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myxoid Liposarcoma. It includes an overview of the trial numbers and their recruitme …
- 畜牛用飼料＆飼料添加剤の世界市場：トウモロコシ、脱脂大豆、小麦、油料種子、穀物、ビタミン、ミネラル、アミノ酸、酵素、酸味料、抗生物質、抗酸化剤The cattle feed market is projected to grow at a CAGR of 2.7% from 2015 to 2020 and reach a projected value of USD 72.12 Billion by 2020. The cattle feed additives market is projected to grow at a CAGR of 3.9% from 2015 to 2020, to reach USD 2.72 Billion by 2020. The livestock sector has developed rapidly; however, it is still largely composed of small-scale farms, especially in developing countri …
- ブラジル・ロシア・インド・中国の股関節置換手術動向（～2020）BRIC Hip Replacement Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Hip Replacement Procedures Outlook to 2020", provides key procedures data on the BRIC Hip Replacement Procedures. The report provides procedure volumes within market segments - Primary Hip Replacement Procedures (Primary Cemented and Cementless Hip Replacement Procedures and Unilateral and Bilateral Primary Hip …
- 商用・軍事用パラシュートの世界市場2017-2021ABSTRACTAbout Commercial and Military Parachute Parachutes are devices used to reduce aerodynamic motion of an object by creating drag (or lift for ram-air parachutes used in paragliding) to drop payloads including people, equipment, bombs, and relief aids from airborne platforms. Historically, parachutes were made using lightweight silk materials; however, most modern parachutes are made using ny …
- 化学防護服の世界市場予測There are numerous chemicals in an industrial working environment which can affect unprotected skin of a person. These toxic chemical may come in contact with the dermatitis layer present on the skin and can enter into human body, which adversely affect the human body. The use of chemical protective clothing can reduce the risk of exposure to hazardous chemicals and provide the last line of defens …
- ヘアマスクの世界市場：性質別（ナチュラル、オーガニック、および合成）、エンドユーザー別（家庭用、商業用）、流通経路別（オンライン、オフライン）The global hair mask market was valued at $597.7 million in 2018 and is projected to reach $886.4 million by 2026, growing at a CAGR of 5.1% from 2019 to 2026. The global hair mask market is segmented on the basis of nature, application, distribution channel, and region. Based on product type, the market is classified into natural, organic and synthetic. By application, the market is segmented int …
- 乾性角結膜炎(ドライアイ)：世界の治験レビュー（2015年上半期版）Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2015" provides data on the Keratoconjunctivitis sicca (Dry Eye) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Keratoconjunctivitis sicca (Dr …
- 膿痂疹治療の世界市場2019-2023About this market The evolving resistance of microorganisms is likely to push growth in the market. There has been evolving resistance owing to the frequent usage of oral antibiotics. Hence manufacturers are developing more effective antibiotics to treat skin infections. Technavio’s analysts have predicted that the impetigo treatment market will register a CAGR of about 7% by 2023. Market Overview …
- 世界の医薬品添加物市場：糖質、オレオケミカル、石油化学品、ポリマーなどThe pharmaceutical excipients market has a high-growth potential because a majority of the drugs are going off-patent in the forecast period, which in turn leads to an increase in demand for pharmaceuticals for generics products. In contrast, the stringent regulations appear to restraint the growth of the overall market to a certain extent. Besides the structural market drivers, there are strong g …
- タンパク質成分の世界市場：動物性タンパク質、植物性タンパク質Food & beverage, animal feed, cosmetics & personal care product, and the pharmaceutical have witnessed tremendous growth over the years owing to growing level of demand from end users for nutritional and health benefiting products. This has substantially benefited the protein ingredients industry, as an upsurge in the demand was witnessed. New technologies have initiated the emergence of innovativ …
- イタリアの癌診断・検査市場2014This report provides an overview of the Italian cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.Table of ContentsBusiness EnvironmentMarket StructureMarket Size, Growth, and Major Suppliers' Market SharesList of TablesTest Volume Forecasts by Market Segment …
- ソフトウェア定義（SDx）の世界市場予測（～2022）：ソフトウェア定義ネットワーク （SDN）、ソフトウェア定義データセンター （SDDC）、ソフトウェア定義ストレージ （SDS）The software-defined anything market is expected to grow at a CAGR of 31.72% between 2016 and 2022, to reach from USD 3.89 Billion in 2015 to USD 28.09 Billion by 2022. Major growth drivers of the market are centralized security control throughout the enterprise, dynamic provisioning of networking resources, reduced operational cost, easy Quality of Service (QoS) implementation, and unified cloud …
- 自動車用試験装置の世界市場：エンジン動力計、シャシー動力計、自動車排ガス試験装置、ホイールアライメント試験機The automotive test equipment market, in terms of value, is projected to grow at a CAGR of 6.29% from 2016 to 2021. The market is estimated to be USD 442.9 Million in 2016, and is projected to reach USD 600.7 Million by 2021. Asia-Pacific is estimated to be the largest market for automotive test equipment, followed by Europe and North America. The growth of the automotive test equipment market is …
